MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare, a leading provider of venture and growth buyout capital to emerging healthcare companies, announces that Remy Durand has joined the Frazier Life Sciences team as a Senior Associate to focus on investment identification, due diligence, and deal closing.
Prior to joining Frazier Healthcare, Remy was a member of the investment team at GE Ventures and a management consultant in L.E.K. Consulting’s life science practice. Remy has also worked with several start-ups, including Maya Medical (acquired by Covidien) and Northstar Neuroscience.
Remy received a Ph.D. in bioengineering from Stanford University, where his doctoral research focused on using optogenetic tools to map neural circuits in the brain and to understand the basis of functional neural imaging. He also holds a B.S.E. degree in biomedical engineering from Case Western Reserve University.
“We are very excited to have Remy join the Life Sciences team at Frazier,” stated Patrick Heron, managing general partner. “Remy’s background of working in start-ups and strategy consulting for life sciences companies positions him well to partner with entrepreneurs to help build their pharmaceutical companies.”
About Frazier Healthcare
Founded in 1991, Frazier Healthcare is a leading provider of growth capital to healthcare companies. With over $2 billion under management, Frazier Healthcare has invested in more than 150 companies across the entire development spectrum. From venture investments to leveraged recapitalizations, Frazier Healthcare has established itself among entrepreneurs and seasoned executives as a preferred partner to help create and grow successful healthcare companies. The Life Sciences team at Frazier focuses on investments in therapeutics and related areas that are addressing unmet medical needs through innovation.
For more information about Frazier Healthcare, visit the company's website at www.frazierhealthcare.com.
